Daschner C, Kleber ME, Stach K, Yuecel G, Husain-Syed F, Ayasse N, Berg AH, März W et al.
Carbamylated albumin (C-Alb) was assessed in 3,193 LURIC participants with no or mild chronic kidney disease followed for 10 years. C-Alb correlated with coronary artery disease severity (Friesinger score r = 0.082, p < 0.001) and improved all-cause mortality AUC from 0.719 to 0.735, with pulse pressure the strongest mortality predictor across C-Alb tertiles. These results support C-Alb as a biomarker linking carbamylation, inflammation, and cardiovascular risk stratification.
Cardiorenal Medicine, 19. Dezember 2024 | PMID 39701045